| 2026-09-11 17:14 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Debt repricing transaction reducing interest margins; no M&A signal detected. |
SEC · detail |
| 2026-08-12 17:17 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings announcement via 8-K Item 2.02 with no M&A-related language or strategic implications. |
SEC · detail |
| 2026-07-08 08:33 |
8-K |
["5.02"] |
other |
0.05
|
Amendment clarifying committee assignments for newly appointed board member. No M&A signal. |
SEC · detail |
| 2026-07-08 08:31 |
8-K |
["5.02", "7.01", "9.01"] |
officer change |
0.25
|
Board appointments of two independent directors with healthcare/medical leadership backgrounds; routine governance action with no M&A language. |
SEC · detail |
| 2026-06-01 16:45 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings announcement with no M&A signals or strategic transaction indicators. |
SEC · detail |
| 2026-05-18 06:15 |
8-K |
["1.01", "1.02", "3.02", "3.03", "5.02", "5.03", "8.01"] |
other |
0.05
|
IPO-related 8-K filing with standard underwriting, governance, and equity plan disclosures. No M&A indicators. |
SEC · detail |